Find Vodobatinib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

API REF. PRICE (USD/KG)

$
$ 0

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Regulatory FDF Prices

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

API

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1388803-90-4, Sco-088, K0706, K-0706, Vodobatinib [usan], N8q12ku2sw
Molecular Formula
C27H20ClN3O2
Molecular Weight
453.9  g/mol
InChI Key
ZQOBVMHBVWNVBG-UHFFFAOYSA-N
FDA UNII
N8Q12KU2SW

Vodobatinib
Vodobatinib is an orally bioavailable, Bcr-Abl tyrosine kinase inhibitor (TKI), with potential antineoplastic activity. Upon administration, vodobatinib selectively targets and binds to the Bcr-Abl fusion oncoprotein, including various Bcr-Abl mutant forms, such as those with the 'gatekeeper' resistance mutation T315I. This inhibits proliferation of Bcr-Abl-expressing tumor cells. The Bcr-Abl fusion protein is an aberrantly activated tyrosine kinase produced by certain leukemia cells. T315I, an amino acid substitution where threonine (T) has been mutated to isoleucine (I) at position 315 in the tyrosine-protein kinase ABL1 portion of the Bcr-Abl fusion protein, plays a key role in resistance to certain chemotherapeutic agents and its expression is associated with poor prognosis.
1 2D Structure

Vodobatinib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
2-chloro-6-methyl-N'-[4-methyl-3-(2-quinolin-3-ylethynyl)benzoyl]benzohydrazide
2.1.2 InChI
InChI=1S/C27H20ClN3O2/c1-17-10-12-22(26(32)30-31-27(33)25-18(2)6-5-8-23(25)28)15-20(17)13-11-19-14-21-7-3-4-9-24(21)29-16-19/h3-10,12,14-16H,1-2H3,(H,30,32)(H,31,33)
2.1.3 InChI Key
ZQOBVMHBVWNVBG-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC1=C(C(=CC=C1)Cl)C(=O)NNC(=O)C2=CC(=C(C=C2)C)C#CC3=CC4=CC=CC=C4N=C3
2.2 Other Identifiers
2.2.1 UNII
N8Q12KU2SW
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. 1388803-90-4

2. Sco-088

3. K0706

4. K-0706

5. Vodobatinib [usan]

6. N8q12ku2sw

7. Vodobatinib (usan)

8. 2-chloro-6-methyl-n'-[4-methyl-3-(2-quinolin-3-ylethynyl)benzoyl]benzohydrazide

9. 2-chloro-6-methyl-n'-(4-methyl-3-(quinolin-3-ylethynyl)benzoyl)benzohydrazide

10. 4-methyl-3-quinolin-3-ylethynylbenzoic Acid N'-(2-chloro-6-methylbenzoyl) Hydrazide

11. Vodobatinib [inn]

12. Unii-n8q12ku2sw

13. Sunk706

14. Vodobatinib [who-dd]

15. Sco088

16. Sun-k706

17. Chembl4130229

18. Schembl15363815

19. Gtpl11191

20. Glxc-26172

21. Ex-a6146

22. Bdbm50590370

23. Who 11506

24. Akos040759561

25. Ms-28258

26. Hy-137460

27. Cs-0138668

28. D11786

29. F88789

30. 2-chloro-6-methyl-n'-(4-methyl-3-(2-(quinolin-3-yl)ethynyl)benzoyl)benzohydrazide

31. 4-methyl-3-quinolin-3-yl-ethynyl Benzoic Acid N'-(2-chloro-6-methylbenzoyl)hydrazide

32. Benzoic Acid, 2-chloro-6-methyl-, 2-(4-methyl-3-(2-(3-quinolinyl)ethynyl)benzoyl)hydrazide

2.4 Create Date
2015-02-13
3 Chemical and Physical Properties
Molecular Weight 453.9 g/mol
Molecular Formula C27H20ClN3O2
XLogP36
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count3
Rotatable Bond Count4
Exact Mass g/mol
Monoisotopic Mass g/mol
Topological Polar Surface Area71.1
Heavy Atom Count33
Formal Charge0
Complexity774
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

ABOUT THIS PAGE

Looking for 1388803-90-4 / Vodobatinib API manufacturers, exporters & distributors?

Vodobatinib manufacturers, exporters & distributors 1

65

PharmaCompass offers a list of Vodobatinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Vodobatinib manufacturer or Vodobatinib supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Vodobatinib manufacturer or Vodobatinib supplier.

PharmaCompass also assists you with knowing the Vodobatinib API Price utilized in the formulation of products. Vodobatinib API Price is not always fixed or binding as the Vodobatinib Price is obtained through a variety of data sources. The Vodobatinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Vodobatinib

Synonyms

1388803-90-4, Sco-088, K0706, K-0706, Vodobatinib [usan], N8q12ku2sw

Cas Number

1388803-90-4

Unique Ingredient Identifier (UNII)

N8Q12KU2SW

About Vodobatinib

Vodobatinib is an orally bioavailable, Bcr-Abl tyrosine kinase inhibitor (TKI), with potential antineoplastic activity. Upon administration, vodobatinib selectively targets and binds to the Bcr-Abl fusion oncoprotein, including various Bcr-Abl mutant forms, such as those with the 'gatekeeper' resistance mutation T315I. This inhibits proliferation of Bcr-Abl-expressing tumor cells. The Bcr-Abl fusion protein is an aberrantly activated tyrosine kinase produced by certain leukemia cells. T315I, an amino acid substitution where threonine (T) has been mutated to isoleucine (I) at position 315 in the tyrosine-protein kinase ABL1 portion of the Bcr-Abl fusion protein, plays a key role in resistance to certain chemotherapeutic agents and its expression is associated with poor prognosis.

Vodobatinib Manufacturers

A Vodobatinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Vodobatinib, including repackagers and relabelers. The FDA regulates Vodobatinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Vodobatinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

Vodobatinib Suppliers

A Vodobatinib supplier is an individual or a company that provides Vodobatinib active pharmaceutical ingredient (API) or Vodobatinib finished formulations upon request. The Vodobatinib suppliers may include Vodobatinib API manufacturers, exporters, distributors and traders.

Vodobatinib GMP

Vodobatinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Vodobatinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Vodobatinib GMP manufacturer or Vodobatinib GMP API supplier for your needs.

Vodobatinib CoA

A Vodobatinib CoA (Certificate of Analysis) is a formal document that attests to Vodobatinib's compliance with Vodobatinib specifications and serves as a tool for batch-level quality control.

Vodobatinib CoA mostly includes findings from lab analyses of a specific batch. For each Vodobatinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Vodobatinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Vodobatinib EP), Vodobatinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Vodobatinib USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty